The DOI matches its Crossref record.
Dolutegravir and weight gain: an unexpected bothering side effect?
Abstract
We recently analyzed, in our real-life cohort of 2260 HIV-infected patients, the reasons for discontinuation of dolutegravir-based combined antiretroviral therapies (cARTs) [1]. Of 517 patients, 55 (10.6%) discontinued this cART due to adverse effects. Unexpectedly, four (7%) of these adverse effects were abnormal weight gain, which ranged between 4 and 12 kg. This prompted us to assess, retrospectively, the evolution of weight and BMI (kg/m2) among the 462 patients who received this cART for more than 6 months. Mean age of these patients was 50.1 years, and 65% were men. At baseline, mean CD4+ lymphocyte cell count was 591 cells/μl (range 5–2010). Most patients (94%) were already receiving cART, and plasma HIV-1 RNA was suppressed for 92% of them. Dolutegravir was mostly associated with abacavir/lamivudine (48%) or tenofovir/emtricitabine (32%) [1]. Finally, BMI was less than 18 kg/m2 (class I) for 6% of the patients, ranging between 18 and 25 kg/m2 (II) in 59%, and between 25 and 30 kg/m2 (III) in 24%, and was more than 30 kg/m2 (IV), indicating obesity, in 6%. Mean time from baseline to weight/BMI assessments was 276 ± 79 days. At this time point, mean weight gain was 3 kg (P = 0.009) and mean BMI increase was 1 kg/m2 (P = 0.002) (Fig. 1). We observed, for 20% of the patients, a more than 10% weight increase compared with baseline, whereas a 4–10% weight increase was observed for 27% of the patients. In addition, during follow-up, in 13% of the patients, BMI increased from class II to class III, and, in 9% of the patients with class III, BMI increased toward class IV. We further found that mean increases in BMI and weight were significant for women, whereas they only showed a tendency toward significancy for men. Finally, these increases were particularly significant for women receiving abacavir/lamivudine and dolutegravir, in whom weight increased from 57 to 62 kg (P = 0.009) (Fig. 1a) and BMI increased from 22 to 24 kg/m2 (P = 0.01) (Fig. 1b).Fig. 1: Evolution of weight (kg) (a) and BMI (kg/m2) (b) after 1 year on a dolutegravir-based regimen.P = Anova. M/ABC+, men on dolutegravir + abacavir; W/ABC+, women on dolutegravir + abacavir.A recent study conducted in 41 149 HIV-infected patients from the D:A:D cohort showed that a high level of BMI may be associated with serious non-AIDS events [2]. In addition, body fat changes can be deleterious to self-perception and HAART adherence [3]. Gains in central fat in HIV-positive patients were strongly associated with protease inhibitors of earlier generation. However, McComsey et al.[4] showed recently, in a large randomized ART-initiation trial including 328 patients, that central and peripheral fat changes did not differ after 96 weeks of treatment containing either two boosted protease inhibitors (including darunavir and atazanavir) or the integrase strand transfer inhibitor (INSTI) raltegravir (+1 kg/m2 in 3.8–4.7% of the patients). There are, to our knowledge, no data on the effect of other INSTIs on body composition. Nevertheless, an in-vitro study showed that, in contrast with raltegravir, elvitegravir altered adipocytes differentiation and function, although less than efavirenz [5]. Hence, our preliminary finding incites the need to monitor, in other large cohorts, the effect of dolutegravir on body weight, BMI, and fat changes at various body sites. Pharmacological assessments may be helpful to explain the more significant rise observed for BMI and weight in women on dolutegravir/abacavir/lamivudine. Acknowledgements Conflicts of interest The authors have no conflicts of interest to declare. Funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sax, P. E., Erlandson, K. M., Lake, J. E., Mccomsey, G. A., Orkin, C., Esser, S., Brown, T. T., Rockstroh, J. K., Wei, X., Carter, C. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz999 · Cited by 768
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy
Bourgi, K., Rebeiro, P. F., Turner, M., Castilho, J. L., Hulgan, T., Raffanti, S. P., Koethe, J. R., & Sterling, T. R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz407 · Cited by 327
Bourgi, K., Jenkins, C. A., Rebeiro, P. F., Shepherd, B. E., Palella, F., Moore, R. D., Althoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25484 · Cited by 246
Obesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
Kuo, P.-H., Sun, H.-Y., Chuang, Y.-C., Wu, P.-Y., Liu, W.-C., & Hung, C.-C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.12.029 · Cited by 61
Metadata
- Authors
- Menard, A., Meddeb, L., Tissot-Dupont, H., Ravaux, I., Dhiver, C., Mokhtari, S., Tomei, C., Brouqui, P., Colson, P., & Stein, A.
- Venue
- AIDS
- Published
- 2017-06-19
- Volume
- 31
- Issue
- 10
- Pages
- 1499-1500
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2621358721
- Cited by
- 163
- References
- 0
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dolutegravir and weight gain: an unexpected bothering side effect? https://app.cochat.ai/papers/10.1097/qad.0000000000001495
- The paper
- Menard, A., Meddeb, L., Tissot-Dupont, H., Ravaux, I., Dhiver, C., Mokhtari, S., Tomei, C., Brouqui, P., Colson, P., & Stein, A. (2017). Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. https://doi.org/10.1097/qad.0000000000001495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.